ACUTE AND SUBACUTE GASTROINTESTINAL AND GENITOURINARY TOXICITY PROFILES OF METFORMIN VERSUS PLACEBO PLUS PROSTATE AND PELVIC RADIOTHERAPY FOR THE MANAGEMENT OF HIGH RISK PROSTATE CANCER: INTERIM TOXICITY RESULTS OF A DOUBLE-BLINDED, MULTICENTRE, PHASE II RANDOMIZED CONTROLLED TRIAL

被引：0

作者：

McDonald, Megan O. ^{[1
]}

Usmani, Nawaid ^{[2
]}

Ong, Aldrich ^{[1
]}

Koul, Rashmi ^{[1
]}

Dubey, Arbind ^{[1
]}

Ahmed, Shahida ^{[1
]}

Quon, Harvey ^{[3
]}

Yee, Don ^{[2
]}

Parliament, Matthew ^{[2
]}

Sivananthan, Gokulan ^{[1
]}

Danielson, Brita ^{[2
]}

Rowe, Lindsay ^{[2
]}

Rose, James ^{[4
]}

Hunter, William ^{[1
]}

Sanghera, Karan Paul ^{[2
]}

Ghosh, Sunita ^{[2
]}

Kim, Julian O. ^{[1
]}

机构：

[1] Univ Manitoba, Winnipeg, MB, Canada

[2] Univ Alberta, Edmonton, AB, Canada

[3] Univ Calgary, Calgary, AB, Canada

[4] Univ British Columbia, Vancouver, BC, Canada

来源：

RADIOTHERAPY AND ONCOLOGY | 2020年 / 150卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S4 / S5

页数：2

共 28 条

[21] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)
Taplin, Mary-Ellen
Gleave, Martin
Evans, Christopher P.
Efstathiou, Eleni
Kantoff, Philip W.
Ross, Ashley
Shore, Neal D.
Briganti, Alberto
Hadaschik, Boris A.
Heidenreich, Axel
Rooney, Oliver Brendan
Tian, Shaozhou Ken
Wetherhold, Lisa
Xu, Weichun
Cheng, Shinta
Brookman-May, Sabine Doris
Lopez-Gitlitz, Angela
Kibel, Adam S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[22] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
Taplin, Mary-Ellen
Gleave, Martin
Evans, Christopher P.
Efstathiou, Eleni
Kantoff, Philip W.
Ross, Ashley
Shore, Neal D.
Briganti, Alberto
Hadaschik, Boris A.
Heidenreich, Axel
Rooney, Oliver Brendan
Tian, Shaozhou Ken
Wetherhold, Lisa
Xu, Weichun
Cheng, Shinta
Kibel, Adam S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[23] STEREOTACTIC BODY VERSUS CONVENTIONAL FRACTIONATION EXTERNAL BEAM RADIOTHERAPY (EBRT) BOOST FOR HIGH-RISK PROSTATE CANCER (HR-PC); EARLY RESULTS OF PBS: A PHASE II RANDOMIZED TRIAL (NCT03380806)
Gouveia, Andre
Mesci, Aruz
Isfahanian, Naghmeh
Dayes, Ian
Schnarr, Kara Lynne
Quan, Kimmen
Maharaj, Lindsay
Cuthbert, David
Hallock, Abhiram
Douvi, Georgia
Lukka, Himu
Goldberg, Mira
Wright, Jim
Swaminath, Anand
Chow, Tom
Diamond, Kevin
Ewusie, Joycelyne
Hajdok, George
Tsakiridis, Theodoros
RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S13 - S14
[24] Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.
Tran, Phuoc T.
Lowe, Kathryn
Wang, Hao
Tsai, Hua-Ling
Song, Daniel Y.
Hung, Arthur
Hearn, Jason W. D.
Lotan, Tamara L.
Paller, Channing Judith
Markowski, Mark Christopher
Denmeade, Samuel R.
Carducci, Michael Anthony
Eisenberger, Mario A.
Orton, Matthew
Deville, Curtiland
Liauw, Stanley L.
Heath, Elisabeth I.
Desai, Neil B.
Beer, Tomasz M.
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).
Kibel, Adam S.
Gleave, Martin
Brookman-May, Sabine D.
Kim, Won
Evans, Christopher P.
Efstathiou, Eleni
Kantoff, Philip W.
Ross, Ashley
Shore, Neal D.
Briganti, Alberto
Hadaschik, Boris A.
Heidenreich, Axel
Rooney, Oliver Brendan
Tian, Shaozhou Ken
Wetherhold, Lisa
Xu, Weichun
Parsons, J. Kellogg
Yeruva, Kesav
Taplin, Mary-Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[26] Acute Gastrointestinal Toxicity Results from a Multi-Institution, Phase 2, Randomized Controlled Trial Comparing 3D-Conformal Radiotherapy (3DCRT) Versus Intensity Modulated Radiotherapy (IMRT) for Locally-Advanced Rectal Cancer (TRI-LARC).
Wallace, N.
Skourou, C.
Dunne, M.
Gillham, C.
McVey, G.
Armstrong, J. G.
Cunningham, M.
Rangaswamy, G.
Mahon, M.
Bradshaw, S.
Sharma, D.
Hennessy, B. T.
Mcdermott, R.
Shannon, A. M.
Osullivan, L.
Parker, I.
Toomey, S.
Marron, J.
O'Neill, B. D.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S151 - S151
[27] PHASE III MULTI-INSTITUTIONAL TRIAL OF ADJUVANT CHEMOTHERAPY WITH PACLITAXEL, ESTRAMUSTINE, AND ORAL ETOPOSIDE COMBINED WITH LONG-TERM ANDROGEN SUPPRESSION THERAPY AND RADIOTHERAPY VERSUS LONG-TERM ANDROGEN SUPPRESSION PLUS RADIOTHERAPY ALONE FOR HIGH-RISK PROSTATE CANCER: PRELIMINARY TOXICITY ANALYSIS OF RTOG 99-02
Rosenthal, Seth A.
Bae, Kyoungwha
Pienta, Kenneth J.
Sobczak, Mark L.
Asbell, Sucha O.
Rajan, Raghu
Kerlin, Kevin J.
Michalski, Jeff M.
Sandler, Howard M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03): : 672 - 678
[28] Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9-to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
Li, Yi
Jing, Quanmin
Wang, Bing
Wang, Xiaozeng
Li, Jing
Qiao, Shubing
Chen, Shaoliang
Angiolillo, Dominick J.
Han, Yaling
AMERICAN HEART JOURNAL, 2020, 228 : 1 - 7

← 1 2 3 →